Navigation Links
AMRI and Codexis Announce Technology Collaboration
Date:2/13/2013

ALBANY, N.Y. and REDWOOD CITY, Calif., Feb. 13, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) and Codexis (NASDAQ: CDXS) announced today that they have entered into a SMARTSOURCING™ partnership. The collaboration will provide opportunities to combine the two companies' capabilities and technologies for specific customer projects, yielding increased value to customers in the form of potentially lower costs, greater yields, cleaner processes and/or faster turnaround times.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Under this non-exclusive, two-year agreement, the companies will align their respective strengths to identify and implement new and improved manufacturing routes for selected Active Pharmaceutical Ingredients (APIs). Combining Codexis' directed evolution technology that enables rapid enzyme discovery and optimization with AMRI's process development and manufacturing capabilities, including utilizing AMRI's proprietary microbial strains, creates synergies that will broaden both companies' ability to offer customers cost-effective, efficient, and sustainable manufacturing processes.

"We are pleased to announce this partnership with Codexis, a company that shares our philosophy of prioritizing scientific problem solving, innovation and customer service," said AMRI's Chairman, President and CEO, Thomas E. D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis' cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer's development projects. This is another example of the AMRI SMARTSOURCING™ strategy of creating partnerships to deliver better outcomes to our customers."

"Codexis selected AMRI for this collaboration because AMRI understands the opportunity to  use biocatalysis for effective and comprehensive route assessment and manufacturing," says Dr. Peter Seufer-Wasserthal, SVP Pharmaceuticals, Codexis Inc. "Both companies have established strong reputations in the pharmaceutical manufacturing industry. By working together, AMRI and Codexis should identify more opportunities, which will benefit both companies and their customers by developing innovative, cost-effective and practical chemical processes."

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

About Codexis Inc.
Codexis, Inc. is a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals. Codexis' product lines include CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol. Partners and customers include global leaders such as Merck, Pfizer and Arch Pharmalabs. For more information, see www.codexis.com.


'/>"/>
SOURCE AMRI; Codexis
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Interim Chief Executive Officer to Present at Jefferies Conference
2. Codexis to Present at the Pacific Crest and Jefferies Conferences
3. Codexis Names Wes Bolsen VP and Chief Marketing Officer
4. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
5. AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
8. The In View Series Announces Plans for a New Series on 3D-Printing
9. Qualitas Health and Valicor Renewables Announce Strategic Partnership to Commercialize Algae-Based Omega-3 Supplements
10. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
11. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... of a newly re-branded identity. The new Media Cybernetics corporate branding reflects a ... world of imaging and image analysis. The re-branding components include a crisp, refreshed ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released its ... Beyond. The paper outlines the key trends that are creating both opportunities and ... a lot of highs and lows as the precision agriculture market has grown ...
(Date:5/23/2016)... OXFORD, England , May 23, 2016 ... Wednesday, May 25 th at 10:15 a.m. ET before ... about the role genetically engineered mosquitos can play in controlling ... known carrier of the Zika virus.      (Logo: ... genetically engineered male mosquito with a self-limiting gene. Trials in ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):